En
No usar ácido acetilsalicílico como prevención primaria en personas sin enfermedad cardiovascular.
Año: 2013
Sociedad Científica: Sociedad Española de Medicina Interna (SEMI)
Más información:

Antithrombotic Trialist Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1949-60

Raju N, Sobieraj-Teague M, Hirsh J et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011;124:621-9.

Seshasai SRK, Wijesuriya S, Sivakumaran R et al. Effect of aspirin on vascular and nonvascular outcomes. Meta-analysis of randomized controlled trials. Arch Intern Med 2012;172:209-16.

US Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. Ann Intern Med 2009;150:396-404.

Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012;33:1635-1701